Drug Profile

Research programme: mRNA-encoded antibodies - BioNTech

Alternative Names: RiboMABs^®

Latest Information Update: 03 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BioNTech
Class Antineoplastics; Bispecific antibodies; RNA
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Oct 2023 Preclinical development in cancer is ongoing Germany (BioNTech website, October 2023)
28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in Germany (IV, Injection)
25 Nov 2020 BioNtech and InstaDeep agree to co-develop RiboMab platform based mRNA-encoded antibodies for Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com